


Well tolerated with an excellent safety profile at all doses



More than 29 million patient-years of experience¹⁹

- More than 10 billion tablets sold worldwide¹⁹
- More than 400 ongoing and completed trials¹⁹
- More than 80,000 patients have been enrolled in studies around the world¹⁹

Low discontinuation rates in clinical trials¹⁹ Discontinuation due to associated adverse events



Pooled data from 3 comparative trials of patients taking either atorvastatin (10-20 mg, n=1148), simvastatin (10-20 mg, n=45), pravastatin (20-40 mg, n=78), or lovastatin (20-40 mg, n=260) for 52 weeks.

*Clinical trials did not include Baycol® (cerivastatin sodium).
Baycol is a registered trademark of Bayer Corp.

Most common side effects related to LIPITOR® (atorvastatin calcium) (%)

	Placebo n=270	10 mg n=863	80 mg n=94
Constipation	1.8	2.1	1.1
Flatulence	3.3	2.1	1.1
Dyspepsia	4.1	2.3	2.1
Abdominal pain	0.7	2.8	2.1

- In a large clinical study, discontinuation of medication and study visits due to adverse events was approximately equal (2%) for both LIPITOR 80 mg and placebo^{19†}


[†]A multicenter, randomized, double-blind, placebo-controlled, 16-week trial that compared atorvastatin 80 mg (n=1538) with placebo plus usual care (n=1548) in 3086 patients with unstable angina or non-Q-wave acute myocardial infarction.

Well tolerated in clinical trials, with an excellent safety profile at all doses



Liver enzymes

- 0.7% of patients treated with LIPITOR® (atorvastatin calcium) experienced increased ALT values $>3 \times$ ULN occurring on 2 or more occasions



Based on a patient population that experienced $>3 \times$ ULN occurring on 2 or more occasions. Incidence of ALT abnormalities was 0.2%, 0.2%, 0.6%, and 2.3% for atorvastatin 10, 20, 40, and 80 mg, respectively. In placebo-controlled trials, 0.4% (n=270) of patients on placebo experienced clinically important ALT elevations.

Skeletal muscles

- CPK $>10 \times$ ULN occurred in less than 0.1% of patients¹⁹
- While muscle-related side effects are rare, physicians should be aware of signs of myalgia (muscle pain and weakness without inflammation), myositis/myopathy (muscle pain and weakness in the presence of inflammation/damage, with raised CPK), and rhabdomyolysis (severe muscle breakdown with grossly raised CPK)

References

1. Libby P. Changing concepts of atherogenesis. *J Intern Med.* 2000;247:349-358.
2. Vogel RA. Cholesterol lowering and endothelial function. *Am J Med.* 1999;107:479-487.
3. Libby P. The vascular biology of atherosclerosis. In: Braunwald E, Zipes DP, Libby P, eds. *Heart Disease: A Textbook of Cardiovascular Medicine*. 6th ed. Philadelphia, Pa: WB Saunders Co; 2001:995-1009.
4. Miller M. The epidemiology of triglyceride as a coronary artery disease risk factor. *Clin Cardiol.* 1999;22(suppl II):II-1-II-6.
5. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Koletis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. *N Engl J Med.* 1987;316:1371-1375.
6. Rössig L, Dimmeler S, Zeiher AM. Apoptosis in the vascular wall and atherosclerosis. *Basic Res Cardiol.* 2001;96:11-22.
7. Libby P. Molecular bases of the acute coronary syndromes. *Circulation.* 1995;91:2844-2850.
8. Nissen SE, for the National Lipid Education Council. Intra-vascular ultrasound and angiography: exploring therapeutic options [presentation on CD-ROM]. New York, NY: Physician's World Communications; 1999.
9. Kannel WB. Importance of hypertension as a major risk factor in cardiovascular disease. In: Genest J, Koiw E, Kuchel O, Boucher R, Nowaczynski W, Rojo-Ortega JM, eds. *Hypertension: Physiopathology and Treatment*. New York, NY: McGraw-Hill Book Co; 1977:888-910.
10. Wilson PWF, Kannel WB, Silbershatz H, D'Agostino RB. Clustering of metabolic factors and coronary heart disease. *Arch Intern Med.* 1999;159:1104-1109.
11. MacMahon SW, Macdonald GJ, Blacket RB. Plasma lipoprotein levels in treated and untreated hypertensive men and women: the National Heart Foundation of Australia Risk Factor Prevalence Study. *Arterioscler.* 1985;5:391-396.
12. Castelli WP. Epidemiology of coronary heart disease: The Framingham Study. *Am J Med.* 1984;76:4-12.
13. Gotto AM Jr, LaRosa JC, Hunninghake D, and the Task Force on Cholesterol Issues. The cholesterol facts: a summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. Dallas, Tex: AHA Medical/Scientific Statement—Special Report. *Circulation.* 1990;81:1721-1733.
14. Criqui MH, Golomb BA. Epidemiologic aspects of lipid abnormalities. *Am J Med.* 1998;105:48S-57S.
15. Wood D, De Backer G, Faergeman O, Graham I, Mancina G, Pyörälä K, with members of the Task Force. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. *Eur Heart J.* 1998;19:1434-1503.
16. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). *JAMA.* 2001;285:2486-2497.
17. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease—The Framingham Heart Study. *Can J Cardiol.* 1988;4(suppl A):5A-10A.
18. World Health Organization. The WHO MONICA Project Web site. Available at: <http://www.ktl.fi/monica/>. Accessed November 2, 2001.
19. Data on file. Pfizer Inc., New York, NY.
20. Pitt B, Waters D, Brown WV, et al, for the Atorvastatin versus Revascularization Treatment Investigators. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. *N Engl J Med.* 1999;341:70-76.
21. Schwartz GG, Olsson AG, Ezekowitz MD, et al, for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial. *JAMA.* 2001;285:1711-1718.
22. Downs JR, Clearfield M, Weis S, et al, for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. *JAMA.* 1998;279:1615-1622.
23. Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. *N Engl J Med.* 1995;333:1301-1307.
24. Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. *N Engl J Med.* 1996;335:1001-1009.
25. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. *N Engl J Med.* 1998;339:1349-1357.
26. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet.* 1994;344:1383-1389.
27. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJP, Stalenhoef AFH. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial. *Lancet.* 2001;357:577-581.
28. IMS National Prescription Audit; May 2001.
29. Jones P, Kafonek S, Laurora I, Hunninghake D, for the CURVES Investigators. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES Study). *Am J Cardiol.* 1998;81:582-587.
30. Dart A, Jerums G, Nicholson G, et al. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. *Am J Cardiol.* 1997;80:39-44.
31. Bertolini S, Bon GB, Campbell LM, et al. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. *Atheroscler.* 1997;130:191-197.



Imported by Neopharm Ltd. P.O.Box 3506, Petach-Tiqva 49130 Tel: 03-9373777

